Abstract
In this issue of Blood, Das and colleagues report their results on the use of the Janus kinase 1/2 (JAK1/2) inhibitor ruxolitinib in murine models of hemophagocytic lymphohistiocytosis (HLH), and the HLH-sibling macrophage activation syndrome (MAS).
MeSH terms
-
Animals
-
Inflammation / prevention & control*
-
Janus Kinases / antagonists & inhibitors*
-
Lymphocyte Activation / drug effects*
-
Lymphohistiocytosis, Hemophagocytic / genetics*
-
Lymphohistiocytosis, Hemophagocytic / pathology*
-
Pyrazoles / pharmacology*